Clinical Trial

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Study acronym: PembroSCCOHT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-10-20; most recent amendment 2025-11-24.
Status change: Active, Not Recruiting → Recruiting 2021-08-06
Status change: Not Yet Recruiting → Active, Not Recruiting 2021-07-28
Trial Details
NCT Number NCT04602377
Lead Sponsor ARCAGY/ GINECO GROUP
Collaborators: Merck Sharp & Dohme LLC
Conditions Small Cell Ovarian Carcinoma
Enrollment 27 participants
Start Date 2021-08-04
Primary Completion 2026-06 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2025-11-28